AbstractLong QT syndrome (LQTS) is a disorder of cardiac electrophysiology resulting in life‐threatening arrhythmias; nowadays, only a few drugs are available for the management of LQTS. Focusing our attention on LQT2, one of the most common subtypes of LQTS caused by mutations in the human ether‐à‐go‐go‐related gene (hERG), in the present work, the stereoselectivity of the recently discovered mexiletine‐derived urea 8 was investigated on the hERG potassium channel. According to preliminary in silico predictions, in vitro studies revealed a stereoselective behavior, with the meso form showing the greatest hERG opening activity. In addition, functional studies on guinea pig isolated left atria, aorta, and ileum demonstrated that 8 does not present any cardiac or intestinal liability in our ex vivo studies. Due to its overall profile, (R,S)‐8 paves the way for the design and development of a new series of compounds potentially useful in the treatment of both congenital and drug‐induced forms of LQTS.
摘要长 QT 综合征(LQTS)是一种心脏电生理紊乱,可导致危及生命的心律失常;目前,只有少数药物可用于治疗 LQTS。LQT2是由人类ether-à-go-go相关基因(hERG)突变引起的最常见的LQTS亚型之一,在本研究中,我们将注意力集中在LQT2上,研究了最近发现的mexiletine-derived urea 8对hERG钾通道的立体选择性。根据硅学的初步预测,体外研究显示了其立体选择性,其中间位形式显示出最大的 hERG 开放活性。此外,对豚鼠离体左心房、主动脉和回肠进行的功能研究表明,在我们的体内外研究中,8 不会对心脏或肠道造成任何影响。由于其整体特征,(R,S)-8 为设计和开发一系列新化合物铺平了道路,这些化合物可能有助于治疗先天性和药物诱发的 LQTS。